BioVie Inc

NASDAQ:BIVI  
14.00
-1.05 (-6.98%)
Products, Other Pre-Announcement

BioVie Gets FDA Guidance For Phase 3 Clinical Trial Of BIV201 In HRS-AKI

Published: 06/23/2021 13:59 GMT
BioVie Inc (BIVI) - Biovie Receives FDA Guidance for Phase 3 Clinical Trial of Biv201 in Hrs-aki.
Biovie Inc - Believes That Positive Results From a Single Pivotal Phase 3 Clinical Trial Could Potentially Support Filing of NDA.
Biovie - Based on Communications With FDA, Believes Positive Results Could Potentially Support Eventual Approval of Biv201 for Treatment of Hrs-aki.